bezlotoxumab, Zinplava

 Indications

Reduction in recurrence of Clostridium difficile infection

(CDI) in patients who are receiving antibacterial

drug treatment of CDI and are at a high risk for CDI recurrence.

Action

Binds to Clostridium difficile toxin B and neutralizes

its effects. Therapeutic Effects: Reduced CDI recurrence.

Pharmacokinetics

Absorption: IV administration results in complete

bioavailability.

Distribution: Minimally distributed to tissues.

Metabolism and Excretion: Eliminated primarily

through catabolism.

Half-life: 19 days.

TIME/ACTION PROFILE (blood levels)

ROUTE ONSET PEAK DURATION

IV unknown unknown unknown

Contraindications/Precautions

Contraindicated in: None.

Use Cautiously in: Heart failure; OB, Lactation:

Safety not established; Pedi: Safety and effectiveness not

established.

Adverse Reactions/Side Effects

CV: HF. CNS: headache. GI: nausea. Misc: infusion

reactions, fever.

Interactions

Drug-Drug: None known.

Route/Dosage

IV (Adults): 10 mg/kg as a single dose.

Availability

Solution for injection (requires dilution): 25 mg/

mL.